Detection of in Patients with Severe COVID-19: Diagnostic and Therapeutic Challenges.
Fiche publication
Date publication
juillet 2021
Journal
Journal of fungi (Basel, Switzerland)
Auteurs
Membres identifiés du Cancéropôle Est :
Dr LINDNER Véronique, Dr CHAMARAUX-TRAN Thiên-Nga
Tous les auteurs :
Gerber V, Ruch Y, Chamaraux-Tran TN, Oulehri W, Schneider F, Lindner V, Greigert V, Denis J, Brunet J, Danion F
Lien Pubmed
Résumé
Cases of pneumonia (PCP) in patients suffering from COVID-19 were described in patients with various comorbidities and outcomes. The diagnosis of PCP in these patients is difficult due to clinical and radiological similarities. We carried out this study in order to better describe potentially at-risk patients and their outcomes. We retrospectively analyzed all patients with a PCR performed in bronchoalveolar lavage fluid, tracheal aspirate, or sputum within a month after the COVID-19 diagnosis. Fifty-seven patients with COVID-19 infection were tested for . Among 57 patients with COVID-19, four patients had a concomitant positive PCR. These four patients were elderly with a mean age of 78. Two patients were immunocompromised, and the two others presented only diabetes mellitus. Three patients presented an ARDS requiring transfer to the ICU and mechanical ventilation. All patients presented lymphocytopenia. Three patients had probable PCP, and one had proven PCP. All patients died within two months after hospital admission. These co-infections are rare but severe, therefore, PCP should be considered in case of worsening of the condition of patients with severe COVID-19.
Mots clés
COVID-19, Pneumocystis jirovecii, SARS-CoV-2, fungi, pneumocystosis
Référence
J Fungi (Basel). 2021 Jul 22;7(8):